Skysong Innovations Completes Licensing Agreement with ASU Spinout...

Immunotherapy company backed by $25 million in Series A financing is developing cancer treatments based on novel ASU technology(PRWeb February 10, 2020)Read the full story at https://www.prweb.com/releases/skysong_innovations_completes_licensing_agreement_with_asu_spinout_oncomyx_therapeutics/prweb16896350.htm
Source: PRWeb: Medical Pharmaceuticals - Category: Pharmaceuticals Source Type: news